{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=duvelisib&page=2", "query": { "intervention": "duvelisib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=duvelisib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T14:38:25.998Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02095587", "title": "Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "IPI-145", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2014-03", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2021-03-17", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095587" }, { "nct_id": "NCT04652960", "title": "Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8", "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8", "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Duvelisib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-10-21", "completion_date": "2026-12-03", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04652960" }, { "nct_id": "NCT01882803", "title": "A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2013-06-17", "completion_date": "2020-11-18", "has_results": true, "last_update_posted_date": "2023-09-07", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 24, "location_summary": "Los Angeles, California • Whittier, California • Denver, Colorado + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01882803" }, { "nct_id": "NCT04688658", "title": "Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Kirkwood", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-10-06", "completion_date": "2025-02-01", "has_results": true, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04688658" }, { "nct_id": "NCT04639843", "title": "Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult T-cell Leukemia/Lymphoma", "Extranodal NK-/T-cell Lymphoma, Nasal Type", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma" ], "interventions": [ { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-11-03", "completion_date": "2022-11-03", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639843" }, { "nct_id": "NCT01871675", "title": "Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma", "T-cell Lymphoma" ], "interventions": [ { "name": "IPI-145", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-05", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871675" }, { "nct_id": "NCT04342117", "title": "Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma, Small Lymphocytic", "Lymphoma", "Lymphoma, Non-Hodgkin", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma" ], "interventions": [ { "name": "duvelisib", "type": "DRUG" }, { "name": "PI3K inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-23", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2021-03-17", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Joliet, Illinois • Goshen, Indiana + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Ames", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04342117" }, { "nct_id": "NCT02783625", "title": "Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Relapsed/Refractory T-cell Lymphomas" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "duvelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-05-23", "completion_date": "2026-04-21", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 11, "location_summary": "Stanford, California • Boston, Massachusetts • St Louis, Missouri + 7 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02783625" }, { "nct_id": "NCT07293403", "title": "Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Helper T-Cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Duvelisib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2026-10-01", "completion_date": "2027-11-23", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07293403" }, { "nct_id": "NCT04209621", "title": "Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Lymphocytic Leukemia (SLL)", "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-07-31", "completion_date": "2021-01-22", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-09-28T14:38:25.998Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209621" } ] }